CRDL Cardiol Therapeutics Inc. IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1702123 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | 78,760 |
| R&D expense | 14.02M | 14.01M | 14.22M | 18.96M | 10.87M |
| SG&A expense | 20.30M | 26.26M | 15.56M | 22.37M | 27.87M |
| Operating income | -34.32M | -40.28M | -29.79M | -41.34M | -38.66M |
| Income tax | — | — | — | 0 | 0 |
| Net income | -33.82M | -36.68M | -28.13M | -30.93M | -31.64M |
| EPS (basic) | -0.39 | -0.51 | -0.44 | -0.49 | -0.73 |
| EPS (diluted) | -0.39 | -0.51 | -0.44 | -0.49 | -0.73 |
| Weighted avg. shares (diluted) | 86.99M | 71.57M | 64.46M | 62.51M | 43.22M |
| Balance sheet | |||||
| Cash & equivalents | 21.42M | 30.58M | 34.93M | 59.47M | 83.90M |
| Receivables | 55,727 | 100,366 | 142,745 | 209,923 | 65,739 |
| Current assets | 23.50M | 31.67M | 36.15M | 61.44M | 87.14M |
| PP&E, netmay include right-of-use assets (IFRS) | 118,093 | 195,592 | 337,058 | 295,738 | 356,493 |
| Intangibles | — | — | 210,358 | 294,802 | 379,246 |
| Total assets | 23.62M | 31.86M | 36.70M | 62.03M | 87.88M |
| Current liabilities | 5.66M | 7.01M | 8.30M | 9.80M | 11.57M |
| Total liabilities | 5.74M | 7.14M | 8.45M | 9.83M | 11.64M |
| Shareholders' equity | 17.88M | 24.73M | 28.25M | 52.20M | 76.24M |
| Cash flow statement | |||||
| Operating cash flow | -23.85M | -25.06M | -25.18M | -27.22M | -23.54M |
| Capital expenditure | 24,484 | 21,290 | 64,312 | 74,709 | 12,916 |
| Free cash flow | -23.88M | -25.08M | -25.24M | -27.30M | -23.55M |
| Investing cash flow | -24,484 | -21,290 | -64,312 | -74,709 | -12,916 |
| Financing cash flow | 15.54M | 18.84M | -55,376 | -53,934 | 93.44M |
| Stock-based compensation | 10.70M | 14.28M | 4.16M | 5.01M | 8.50M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.